J
Jeff Szer
Researcher at Peter MacCallum Cancer Centre
Publications - 506
Citations - 20753
Jeff Szer is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 68, co-authored 477 publications receiving 18282 citations. Previous affiliations of Jeff Szer include Royal Melbourne Hospital & Health Science University.
Papers
More filters
Journal ArticleDOI
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Journal ArticleDOI
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
William P. Sheridan,Richard M. Fox,C G Begley,Darryl W. Maher,Katherine M McGrath,Christopher A. Juttner,L. Bik To,Jeff Szer,G. Mostyn +8 more
TL;DR: The ability of filgrastim to mobilise peripheral-blood progenitor cells and assess their efficacy when infused after chemotherapy on recovery of neutrophil and platelet counts was studied in this article.
Journal Article
Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
Andrew Grigg,C G Begley,Christopher A. Juttner,Jeff Szer,Luen Bik To,Darryl W. Maher,Katherine M McGrath,George Morstyn,Richard M. Fox,William P. Sheridan +9 more
TL;DR: The haematopoietic growth factor (HGF), granulocyte colony stimulating factor (G-CSF; filgrastim) substantially shortens the period of severe neutropenia that follows high-dose chemotherapy and autologous bone marrow infusion by stimulating granulopoiesis.
Journal ArticleDOI
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Susan Branford,Zbigniew Rudzki,Sonya Walsh,Ian H. Parkinson,Andrew Grigg,Jeff Szer,Kerry Taylor,Richard Herrmann,John F. Seymour,Christopher Arthur,David Joske,Kevin R. Lynch,Timothy P. Hughes +12 more
TL;DR: The detection of kinase domain mutations using a direct sequencing technique was almost always associated with imatinib resistance, and patients with mutations in the P-loop had a particularly poor prognosis.
Journal ArticleDOI
Hematopoietic stem cell transplantation: a global perspective
Alois Gratwohl,Helen Baldomero,Mahmoud Aljurf,Marcelo C. Pasquini,Luis Fernando Bouzas,Ayami Yoshimi,Jeff Szer,Jeffrey H. Lipton,Alvin Schwendener,Michael Gratwohl,Karl Frauendorfer,Dietger Niederwieser,Mary M. Horowitz,Yoshihisa Kodera,Marrow Transplantation +14 more
TL;DR: Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.